Generation Bio (NASDAQ:GBIO) Earns Outperform Rating from Analysts at William Blair

William Blair started coverage on shares of Generation Bio (NASDAQ:GBIO) in a note issued to investors on Tuesday, The Fly reports. The brokerage set an “outperform” rating on the stock.

Separately, Needham & Company LLC began coverage on shares of Generation Bio in a research note on Thursday, February 18th. They set a “buy” rating and a $50.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Generation Bio currently has a consensus rating of “Buy” and an average price target of $36.75.

Shares of Generation Bio stock traded down $2.70 during midday trading on Tuesday, hitting $34.48. The company had a trading volume of 367,617 shares, compared to its average volume of 800,395. The business’s 50 day simple moving average is $30.72 and its two-hundred day simple moving average is $30.19. Generation Bio has a 1-year low of $17.00 and a 1-year high of $55.72.

In related news, insider Matthew Stanton sold 5,630 shares of Generation Bio stock in a transaction dated Thursday, January 14th. The stock was sold at an average price of $32.54, for a total value of $183,200.20. Following the completion of the sale, the insider now owns 203,784 shares of the company’s stock, valued at approximately $6,631,131.36. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Douglas Kerr sold 11,267 shares of the company’s stock in a transaction that occurred on Monday, January 11th. The stock was sold at an average price of $27.58, for a total transaction of $310,743.86. Following the sale, the insider now directly owns 337,825 shares in the company, valued at approximately $9,317,213.50. The disclosure for this sale can be found here. Insiders have sold a total of 27,437 shares of company stock valued at $890,459 in the last three months.

Large investors have recently bought and sold shares of the company. Penserra Capital Management LLC purchased a new stake in Generation Bio during the 4th quarter valued at $30,000. Morgan Stanley purchased a new position in Generation Bio in the third quarter worth about $59,000. Strs Ohio bought a new position in shares of Generation Bio during the third quarter valued at approximately $95,000. Citigroup Inc. increased its stake in Generation Bio by 571.3% in the fourth quarter. Citigroup Inc. now owns 3,954 shares of the company’s stock worth $112,000 after purchasing an additional 3,365 shares during the period. Finally, New York State Common Retirement Fund purchased a new position in shares of Generation Bio during the third quarter valued at $173,000. 63.26% of the stock is owned by hedge funds and other institutional investors.

Generation Bio Company Profile

Generation Bio Co, a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology.

Recommended Story: Backdoor Roth IRA